Historic CRISPR drug approval heralds new era in Cas9 IP wars
Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.
Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.
Chief Legal Officer Yoori Kim argues that current patent uncertainty should fuel rather than thwart licensing deals
The surge is due to 9,702 US patent assets involved in the BlackBerry sale to Key Patent Innovations, which runs Malikie Innovations, according to the AST Patent Deals Report for Q2 2023
Pathbreaking joint venture between academia and Big Pharma addresses university IP monetisation challenges
12 September 2023
Narrow safe harbor immunity and platform technology patents are creating both pitfalls and opportunities
08 September 2023
NanoString Technologies is facing an injunction at the UPC, which has scheduled several further PI hearings in Munich and Vienna
06 September 2023
IAM speaks exclusively to Christopher Arnot about the crowded CRISPR IP landscape
25 August 2023
Having granted its first injunction ex parte, the Unified Patent Court will soon host formal hearings regarding 10x Genomics’ applications for injunctive relief
22 August 2023
IAM speaks exclusively to Jasper Clube about the CRISPR microbiome IP landscape
18 August 2023
RIS has received attention from a diverse number of players working towards creating SEP portfolios. As the technology progresses and becomes more sophisticated and with the standardisation process underway, an acceleration of patent filings in the coming years is very likely.
02 August 2023
SNIPR Biome has five patents revived but more disputes are on the horizon
18 July 2023
The plot continues to thicken in 10x Genomics’ multi-faceted spat with NanoString
13 July 2023
After winning first ever biotech AASI, 10x Genomics files first ever UP lawsuit
06 June 2023
Unlock unlimited access to all IAM content